香港股市 已收市

Zymeworks Inc. (ZYME)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
9.48+0.23 (+2.49%)
收市價: 04:00PM EST
9.85 +0.37 (+3.90%)
收市後: 07:59PM EST
全螢幕
交易股價資料並非來自所有市場
前收市價9.25
開市9.23
買盤9.42 x 1000
賣出價9.87 x 1000
今日波幅9.18 - 9.93
52 週波幅4.11 - 10.80
成交量679,667
平均成交量1,179,052
市值597.205M
Beta 值 (5 年,每月)0.89
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-4.97
業績公佈日2023年2月22日 - 2023年2月27日
遠期股息及收益率無 (無)
除息日
1 年預測目標價13.45
  • Benzinga

    Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline

    SVB Leerink downgraded Zymeworks Inc (NASDAQ: ZYME) to Market Perform with a price target of $8, down from $19 following the recent divestiture of zanidatamab to Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and the unveiling of the company's early stage pipeline. While the JAZZ/ZYME deal is robust and front-loaded, providing the company with significant free cash flow to fund operations. But based on discussions with JAZZ management, it appears unlikely that the company will opt to pursue some of the

  • Benzinga

    Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal

    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) will acquire development and commercialization rights to Zymeworks Inc's (NASDAQ: ZYME) zanidatamab across all indications in the U.S., Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene Ltd (NASDAQ: BGNE). Zanidatamab, a HER2-targeted bispecific, is currently in pivotal trials as a second-line treatment for HER2-expressing biliary tract cancer (BTC) and first-line treatment for

  • Benzinga

    Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

    Zymeworks Inc (NASDAQ: ZYME) presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors. The data were presented at the European Society for Medical Oncology Annual Congress. A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy. Also R